drugset / Trial / NCT00387725

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

NCT00387725

Phase 2 Completed 127 enrolled Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents

Timeline

Start
2006-11
Primary completion
2008-01
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject rLP2086 Vaccine 20 mg
Subject rLP2086 Vaccine 60 mg
Subject rLP2086 Vaccine 200 mg

Indications

No indication recorded.